Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances

Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease

(2015) Robert Baranello et al.   Current Alzheimer Research

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

(2014) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Neprilysin Inhibition for Heart Failure

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes

(2014) J. Scott Miners et al.   Frontiers in Aging Neuroscience

Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s disease

(2014) Natalia N. Nalivaeva et al.   Frontiers in Aging Neuroscience

Time and Technology Will Tell

(2014) Brent N. Reed et al.   Heart Failure Clinics

Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat

(2013) Jonathan R. Dalzell et al.   Cardiovascular Therapeutics

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

(2013) John J. V. McMurray et al.   EUROPEAN JOURNAL OF HEART FAILURE

Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)

(2013) Sanae Hamaguchi et al.   Journal of Cardiology

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

(2012) et al.   EUROPEAN JOURNAL OF HEART FAILURE

Novel Protein Therapeutics for Systolic Heart Failure

(2012) Horng H. Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

(2011) Laxminarayan G Hegde et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

(2011) C.M. O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Renal effects of ularitide in patients with decompensated heart failure

(2008) Hartmut Lüss et al.   AMERICAN HEART JOURNAL

Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure

(2008) Clyde W. Yancy et al.   Circulation-Heart Failure

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

(2007) R M Fryer et al.   BRITISH JOURNAL OF PHARMACOLOGY